Seminari VHIR - Dra. Ronit Satchi-Fainaro "Reverting cancer's poor prognosis using precision polymeric nanomedicines based on molecular fingerprints of long-term survivors"

 Altres activitats
  Sala d'Actes, planta baixa, Hospital General —
20/11/2018
20/11/2018 -- De 15:30h a 17:00h
Organiza :
Vall d'Hebron Institut de Recerca (VHIR)
Modalidad: Presencial
Compartir:

Dra. Ronit Satchi-Fainaro, ProfessorPhysiology & Pharmacology, Sackler Faculty of Medicine-Tel Aviv University, Israel

"Reverting cancer's poor prognosis using precision polymeric nanomedicines based on molecular fingerprints of long-term survivors"

Tumor progression is dependent on a number of sequential steps, including initial tumor-vascular interactions and recruitment of blood vessels, as well as established interactions of tumor cells with their surrounding microenvironment and its different immune, endothelial and connective cellular and extra-cellular components. Failure of a microscopic tumor, either primary, recurrent or metastatic, to complete one or more of these early stages may lead to delayed clinical manifestation of the cancer. Micrometastasis, dormant tumors, and minimal residual disease, contribute to the occurrence of relapse, and constitute fundamental clinical manifestations of tumor dormancy that are responsible for the majority of cancer deaths. However, although the tumor dormancy phenomenon has critical implications for early detection and treatment of cancer, it is one of the most neglected areas in cancer research and its biological mechanisms are mostly unknown.

We created several patient-derived cancer models mimicking pairs of dormant versus fast-growing, primary versus metastatic and drug-sensitive versus drug-resistant cancers using cutting-edge techniques of patient-derived xenografts, 3D-printing and genetically-modified mouse models. We investigated the molecular changes in tumor-host interactions that govern the escape from dormancy and contribute to tumor progression.
Using our in vitro, ex vivo and in vivo models, we discovered novel targets which provided important tools for the design of novel libraries of cancer nano-sized theranostics (therapeutics and diagnostics) (1-3) that have the potential to be translated to the clinic. Our libraries of precision nanomedicines are synthesized as highly controlled micellar, nanogels, coiled or globular particulated supramolecular structures consisting of linear, hyperbranched or dendritic polymers based on polyglutamic acid (PGA), polyethyleneglycol (PEG), poly(N-(2-hydroxypropyl)methacrylamide) (HPMA) copolymer, polyglycerol (PG), poly(lactic-coglycolic acid) (PLGA) and hybrid systems (4-9). We hypothesize that the acquired knowledge from this multidisciplinary research strategy will revolutionize the way we diagnose and treat cancer.

Host: CIBBIM-Nanomedicine. Drug Delivery and Targeting- simo.schwartz@vhir.org

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Selecciona el boletín que quieres recibir:

La aceptación de estas condiciones, supone que da el consentimiento al tratamiento de sus datos personales para la prestación de los servicios que solicita a través de este portal y, si procede, para hacer las gestiones necesarias con las administraciones o entidades públicas que intervengan en la tramitación, y su posterior incorporación en el mencionado fichero automatizado. Podéis ejercitar los derechos de acceso, rectificación, cancelación y oposición dirigiéndoos por escrito a web@vhebron.net, indicando claramente al asunto "Ejercicio de derecho LOPD".
Responsable: Fundació Hospital Universitari Vall d’Hebron – Institut de Recerca.
Finalidad: Gestionar el contacto del usuario.
Legitimación: Aceptación expresa de la política de privacidad.
Derechos: Acceso, rectificación, supresión y portabilidad de los datos, limitación y oposición a su tratamiento. 
Procedencia: El propio interesado.